Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

about

Test-compatible confidence intervals for adaptive two-stage single-arm designs with binary endpoint.A two-stage design for phase II trials with time-to-event endpoint using restricted follow-up.

P2860

Q48117225-6BBD873C-C9D9-4F53-8783-1DF56411753A Q52562512-2CFB9759-C6DC-41F7-A42B-55C947D0F1F4

P2860

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

Item

http://www.wikidata.org/entity/Q38586537

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Nine-year change in statistica ...... s of Phase II oncology trials.

@en

type

Item

label

Nine-year change in statistica ...... s of Phase II oncology trials.

@en

prefLabel

Nine-year change in statistica ...... s of Phase II oncology trials.

@en

P1476

Nine-year change in statistica ...... s of Phase II oncology trials.

@en

P2093

Anastasia Ivanova

http://www.w3.org/2001/XMLSchema#string

Barry Paul

http://www.w3.org/2001/XMLSchema#string

Guochen Song

http://www.w3.org/2001/XMLSchema#string

Neerali Patel

http://www.w3.org/2001/XMLSchema#string

Olga Marchenko

http://www.w3.org/2001/XMLSchema#string

Stergios J Moschos

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

A three-outcome design for phase II clinical trials.

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Content and quality of currently published phase II cancer trials.

Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Benefit and harms of new anti-cancer drugs.

P304

141-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10543406.2015.1092030

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26368744

http://www.w3.org/2001/XMLSchema#string

P921

Amar

phase II clinical trial

P932

5995106

http://www.w3.org/2001/XMLSchema#string

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

about

P2860

P2860

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932